Stock Information
Halozyme Therapeutics Inc (HALO)
Ticker Symbol: HALO
Exchange: NASDAQ
Sector: Biotechnology
Market Cap: $9,741.12 mil
Piotroski score: 5
PE Ratio: 27.6256
EPS (TTM): 3.3468
Revenue (TTM): $13.73 M
Dividend Yield: N/A%
ROE: 180.63%
Latest News
-
Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?
Fri, Aug 14, 2026 12:04 AM
-
Halozyme (HALO) Q2 2026 Earnings Call Transcript
Thu, Aug 13, 2026 10:28 PM
-
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
Thu, Aug 13, 2026 4:45 PM
-
Is Halozyme Therapeutics (HALO) Stock Outpacing Its Medical Peers This Year?
Thu, Aug 13, 2026 1:40 PM
-
Top 3 Health Care Stocks That May Implode In August
Wed, Aug 12, 2026 8:58 AM
-
HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance
Tue, Aug 11, 2026 9:33 AM
-
Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know
Tue, Aug 11, 2026 4:29 AM
-
1 Profitable Stock to Research Further and 2 We Ignore
Mon, Aug 10, 2026 1:09 PM
-
Halozyme Therapeutics (HALO) Is Up 24.9% After Raising 2026 Revenue Outlook and Boosting Buybacks
Sun, Aug 9, 2026 12:19 AM
-
Is Halozyme Therapeutics (HALO) Fairly Valued As Earnings Beat And Guidance Rise?
Sat, Aug 8, 2026 4:12 PM
Key Financials
Financial data not available
